Fernando Martinez to Clinical Trials as Topic
This is a "connection" page, showing publications Fernando Martinez has written about Clinical Trials as Topic.
Connection Strength
2.752
-
Podolanczuk AJ, Richeldi L, Martinez FJ. The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis. JAMA. 2023 05 09; 329(18):1554-1555.
Score: 0.672
-
Kaner RJ, Bajwa EK, El-Amine M, Gorina E, Gupta R, Lazarus HM, Luckhardt TR, Mouded M, Posada K, Richeldi L, Stauffer J, Tutuncu A, Martinez FJ. Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. Am J Respir Crit Care Med. 2019 07 15; 200(2):133-139.
Score: 0.516
-
Nathan SD, Martinez FJ. Pitfalls in developing new compounds for idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2017 09; 23(5):426-431.
Score: 0.453
-
Chang AC, Chan KM, Martinez FJ. Lessons from the national emphysema treatment trial. Semin Thorac Cardiovasc Surg. 2007; 19(2):172-80.
Score: 0.216
-
Raghu G, Ghazipura M, Fleming TR, Aronson KI, Behr J, Brown KK, Flaherty KR, Kazerooni EA, Maher TM, Richeldi L, Lasky JA, Swigris JJ, Busch R, Garrard L, Ahn DH, Li J, Puthawala K, Rodal G, Seymour S, Weir N, Danoff SK, Ettinger N, Goldin J, Glassberg MK, Kawano-Dourado L, Khalil N, Lancaster L, Lynch DA, Mageto Y, Noth I, Shore JE, Wijsenbeek M, Brown R, Grogan D, Ivey D, Golinska P, Karimi-Shah B, Martinez FJ. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency. Am J Respir Crit Care Med. 2024 03 15; 209(6):647-669.
Score: 0.178
-
Rabe KF, Halpin DMG, Han MK, Miravitlles M, Singh D, Gr?nke L, Vo? F, Martinez FJ. Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respir Res. 2020 Jul 09; 21(1):177.
Score: 0.138
-
Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, Richeldi L, Rose D, Wells AU, Brown KK. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J. 2015 Jul; 46(1):243-9.
Score: 0.096
-
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van M?lken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008 Feb; 31(2):416-69.
Score: 0.058
-
Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther. 2006 Feb; 4(1):101-24.
Score: 0.051
-
Martinez FJ. Acute exacerbation of chronic bronchitis: expanding short-course therapy. Int J Antimicrob Agents. 2005 Dec; 26 Suppl 3:S156-63.
Score: 0.050
-
Yawn BP, Make B, Mannino D, Lopez C, Murray S, Thomashow B, Brown R, Dolor RJ, Joo M, Tapp H, Zittleman L, Meldrum C, Anderson S, Martinez FJ, Han MK. Impact of the COVID-19 Pandemic on Outcomes of CAPTURE: A Primary Care Chronic Obstructive Pulmonary Disease Screening Clinical Trial. Ann Am Thorac Soc. 2024 Jan; 21(1):176-179.
Score: 0.044
-
Cazzola M, Rogliani P, Barnes PJ, Blasi F, Celli B, Hanania NA, Martinez FJ, Miller BE, Miravitlles M, Page CP, Tal-Singer R, Matera MG. An Update on Outcomes for COPD Pharmacological Trials: A COPD Investigators Report - Reassessment of the 2008 American Thoracic Society/European Respiratory Society Statement on Outcomes for COPD Pharmacological Trials. Am J Respir Crit Care Med. 2023 08 15; 208(4):374-394.
Score: 0.043
-
Bafadhel M, Barnes N, Bourke SC, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Jones CE, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Martinez FJ, Wise R, Singh D. A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. Eur Respir J. 2021 09; 58(3).
Score: 0.038
-
Singh D, Bafadhel M, Brightling CE, Sciurba FC, Curtis JL, Martinez FJ, Pasquale CB, Merrill DD, Metzdorf N, Petruzzelli S, Tal-Singer R, Compton C, Rennard S, Martin UJ. Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020 09 01; 202(5):660-671.
Score: 0.035
-
Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, Martinez FJ, Collard HR. Closing the Evidence Gap in Interstitial Lung Disease. The Promise of Real-World Data. Am J Respir Crit Care Med. 2019 05 01; 199(9):1061-1065.
Score: 0.032
-
Wells JM, Parker MM, Oster RA, Bowler RP, Dransfield MT, Bhatt SP, Cho MH, Kim V, Curtis JL, Martinez FJ, Paine R, O'Neal W, Labaki WW, Kaner RJ, Barjaktarevic I, Han MK, Silverman EK, Crapo JD, Barr RG, Woodruff P, Castaldi PJ, Gaggar A. Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene. JCI Insight. 2018 11 15; 3(22).
Score: 0.031
-
Lynch JP, Martinez FJ. Community-acquired pneumonia. Curr Opin Pulm Med. 1998 May; 4(3):162-72.
Score: 0.030
-
Nathan SD, Behr J, Cottin V, Collard HR, Hoeper MM, Martinez FJ, Wells AU. Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy? Respir Med. 2017 01; 122 Suppl 1:S10-S13.
Score: 0.027
-
Vachi?ry JL, Adir Y, Barber? JA, Champion H, Coghlan JG, Cottin V, De Marco T, Gali? N, Ghio S, Gibbs JS, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D100-8.
Score: 0.022
-
Escudero J, Hernandez H, Martinez F. Comparative study of the antihypertensive effect of verapamil and atenolol. Am J Cardiol. 1986 Feb 26; 57(7):54D-58D.
Score: 0.013
-
Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs. 2004; 64(4):405-30.
Score: 0.011